Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-086293
Chunk: 19

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 19
---
 Mr. McFarlane, along with, R. LaDuane Clifton, the Company’s Chief Financial Officer and Treasurer, and Nichol Ochsner, the Company’s Vice President of Investor Relations and Corporate Communications, met with Mr. Mangless via teleconference to introduce Mr. McFarlane as the newly appointed Chief Executive Officer.

On October 22, 2023, Mr. McFarlane and Ms. Ochsner met with Mr. Mangless via teleconference to discuss Mr. Mangless’ concerns with the Company’s operations, including his desire for Dr. Travis Mickle, the Company’s former Chief Executive Officer, President, director, and co-founder, to work in a science-focused role with the Company. Dr. Mickle had resigned as the Company’s Chief Executive Officer, effective as of January 6, 2023, and as a director and the President of the Company, effective as of the date of the 2023 Annual Meeting. Dr. Mickle entered into a Transition Agreement and a Consulting Agreement in connection with his resignation, and continued to provide consulting services to the Company until October 31, 2024. Mr. Mangless additionally sought the Company to reimburse him for his expenses in connection with his solicitation of proxies for the proxy contest he initiated in connection with the 2023 Annual Meeting.

On October 25, 2023, Mr. McFarlane met with Dr. Mickle over lunch for an introductory meeting to discuss the Company’s background as well as Dr. Mickle’s consulting arrangement with the Company.

On November 1, 2023, Mr. McFarlane met with Dr. Mickle via teleconference to discuss the consulting arrangement with the Company and the status of certain deliverables.

On December 28, 2023, Dennis Elko, a stockholder of the Company, sent an email to John B. Bode, a current director of the Company and chair of the nominating and corporate governance committee of the Board (the “Nominating and Corporate Governance Committee”), with suggestions to improve the Company’s corporate governance, including with respect to the Board’s classified structure. Mr. Elko also expressed his disappointment that Mr. Mangless had not been reimbursed for his expenses by the Company in connection with his solicitation of proxies for the proxy contest Mr. Mangless initiated in connection with the 2023 Annual Meeting. Finally, Mr. Elko noted that he was impressed with a recent interview of Mr. McFarlane with Genetic